Current and future therapy in Alzheimer's disease. (Q37165703)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Current and future therapy in Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Robert J van Marum

series ordinal

1

1 reference

18 August 2017

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

Fundamental and Clinical Pharmacology

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

265-274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

Global prevalence of dementia: a Delphi consensus study

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Rationale for combination therapy with galantamine and memantine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Alpha-secretase activation--an approach to Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Cerebral hemorrhage after passive anti-Abeta immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Metal and inflammatory targets for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Dietary intake of fatty acids and fish in relation to cognitive performance at middle age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Experts disagree over NICE's approach for assessing drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Disease-modifying trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

Amyloid-beta in Alzheimer Disease: The Null versus the Alternate Hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1472-8206.2008.00578.X

10.1111/J.1472-8206.2008.00578.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485144 AND SRC:MED&resulttype=core&format=json

7 January 2020

1 reference